Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 41, 2011 - Issue 1
181
Views
2
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

An interspecies extrapolation of the pharmacokinetics of telavancin, a rapidly bactericidal, concentration-dependent antibiotic

&
Pages 82-89 | Received 30 Jun 2010, Accepted 16 Sep 2010, Published online: 15 Oct 2010
 

Abstract

  1. Telavancin is an intravenous lipoglycopeptide antibiotic active against many Gram-positive pathogens via inhibition of bacterial cell wall synthesis and disruption of bacterial membrane function.

  2. Non-compartmental pharmacokinetic parameters of telavancin (clearance [Cl], steady-state volume of distribution [Vss], area under the concentration curve [AUC], and elimination half-life [t1/2]) were determined for five preclinical species (mice, rats, rabbits, dogs, and monkeys). Interspecies scaling was applied to predict the corresponding parameters in humans and compare retrospectively with observed values.

  3. Plasma concentrations of single doses of telavancin declined monoexponentially in all species with half-lives between 1.2 and 2.4 h. The pharmacokinetics of telavancin was demonstrated to be dose-proportional in rabbits and gender-independent in monkeys.

  4. Application of the simple allometric equation (Y = aWb) resulted in a good correlation between predicted and observed values of Vss in humans. Application of a modified allometric equation that includes brain weight (Cl × BW = aWb) resulted in a good correlation between predicted and observed values of Cl, AUC, and t1/2 in humans.

  5. These data suggest that interspecies scaling may be useful to predict pharmacokinetic parameters of telavancin in humans.

Acknowledgements

This study was conducted by Theravance, Inc. The authors thank Stacy M. Adams and Julie D. Seroogy, former employees of Theravance, Inc., for assistance with this work. Editorial support, including writing assistance, was provided by Ed Parr, PhD, a medical writer at Envision Scientific Solutions, and was funded by Astellas Pharma Global Development, Inc.

Declaration of interest

The authors are former employees and stockholders of Theravance, Inc.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 897.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.